159 related articles for article (PubMed ID: 23037732)
1. [JAK2 inhibitors in the treatment of myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2012 Oct; 53(10):1600-7. PubMed ID: 23037732
[No Abstract] [Full Text] [Related]
2. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
3. A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.
Gangat N; Phelps A; Lasho TL; Finke CM; Vallapureddy R; Hanson CA; Ketterling RP; Patnaik MM; Pardanani A; Tefferi A
Blood Cancer J; 2019 Jan; 9(2):11. PubMed ID: 30679417
[No Abstract] [Full Text] [Related]
4. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes R; Mesa RA
Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
[TBL] [Abstract][Full Text] [Related]
6. Hypothesis: how do JAK2-inhibitors work in myelofibrosis.
Mesa R; Gale RP
Leuk Res; 2009 Sep; 33(9):1156-7. PubMed ID: 19450878
[TBL] [Abstract][Full Text] [Related]
7. JAK2 inhibitors: are they the solution?
Santos FP; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S28-36. PubMed ID: 22035745
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibition: the key to treating myeloproliferative neoplasm?
Tibes R; Bogenberger JM; Mesa RA
Expert Rev Hematol; 2012 Dec; 5(6):583-5. PubMed ID: 23216589
[No Abstract] [Full Text] [Related]
9. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Harrison C; Verstovsek S; McMullin MF; Mesa R
Br J Haematol; 2012 May; 157(4):426-37. PubMed ID: 22463737
[TBL] [Abstract][Full Text] [Related]
10. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
[TBL] [Abstract][Full Text] [Related]
11. JAK2 kinase inhibitors and myeloproliferative disorders.
Chen AT; Prchal JT
Curr Opin Hematol; 2010 Mar; 17(2):110-6. PubMed ID: 20087176
[TBL] [Abstract][Full Text] [Related]
12. [Myeloproliferative neoplasms].
Komatsu N
Rinsho Ketsueki; 2013 Jan; 54(1):71-8. PubMed ID: 23391649
[No Abstract] [Full Text] [Related]
13. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Stein BL; Crispino JD; Moliterno AR
Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
[TBL] [Abstract][Full Text] [Related]
15. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.
Winton EF; Kota V
Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase 2 inhibitors in myeloproliferative disorders.
Lucia E; Recchia AG; Gentile M; Bossio S; Vigna E; Mazzone C; Madeo A; Morabito L; Gigliotti V; De Stefano L; Caruso N; Servillo P; Franzese S; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Jan; 20(1):41-59. PubMed ID: 21128825
[TBL] [Abstract][Full Text] [Related]
17. The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.
Quintás-Cardama A
Leuk Res; 2013 Apr; 37(4):465-72. PubMed ID: 23313046
[TBL] [Abstract][Full Text] [Related]
18. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis.
Vannucchi AM
Leuk Res; 2009 Dec; 33(12):1581-3. PubMed ID: 19573914
[TBL] [Abstract][Full Text] [Related]
19. JAK2 inhibitors in myelofibrosis.
Pardanani A
Clin Adv Hematol Oncol; 2011 Nov; 9(11):856-8. PubMed ID: 22252617
[No Abstract] [Full Text] [Related]
20. Therapeutic approaches in myelofibrosis.
Barosi G; Rosti V; Vannucchi AM
Expert Opin Pharmacother; 2011 Jul; 12(10):1597-611. PubMed ID: 21457082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
